Clinical trials
Carboplatin clinical trials
Below are recruiting carboplatin clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT06970639RecruitingPhase 3
Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Guangdong, GuangzhouAges 18 years+ - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07122687RecruitingPhase 2
IBI363 or Pembrolizumab with Chemo before Lung Cancer Surgery
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
Shenyang, LiaoningAges 18–75 - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT06532591RecruitingPhase 2
Cadonilimab plus chemo before and after lung cancer surgery
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
Chengdu, SichuanAges 18–70 - NCT06005324RecruitingPhase 1
Personalized treatment for advanced head and neck cancer
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
Chicago, IllinoisAges 18 years+ - NCT06491082Recruiting
Chemotherapy nerve damage study in solid tumor patients
This study looks at nerve damage (neuropathy) that can happen as a side effect of chemotherapy. It aims to understand how common it is and how it affects people being treated for solid tumors.
DehradunAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06401330RecruitingPhase 3
Wilms tumor treatment study for children and young adults
This study is testing different treatments for children and young adults with a type of kidney cancer called Wilms tumor. The treatment you get depends on certain risk factors, like tumor stage and lab results. The goal is to give the right amount of treatment for each person's situation.
Birmingham, AlabamaAges Up to 30 years - NCT06052839RecruitingPhase 2
Pulsed chemo plus pembrolizumab for head and neck cancer
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT07229599RecruitingPhase 1/Phase 2
MHB036C combined with other treatments for advanced lung cancer
This study tests a new drug called MHB036C combined with other anti-tumor treatments for people with advanced lung cancer or other solid tumors that have not responded to standard therapies. It aims to find a safe and effective dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+ - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT06336707RecruitingPhase 1
HS-20089 combination for advanced solid tumors
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Mobile, AlabamaAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+ - NCT06632327RecruitingPhase 3
Comparing treatment timing for stage II-IIIB lung cancer
This trial is for people with a certain type of lung cancer (non-small cell lung cancer) that can be surgically removed. It tests whether it is better to receive treatment before or after surgery to remove the cancer.
Birmingham, AlabamaAges 18 years+
Hear when a new Carboplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carboplatin?
- Yes. Clin2 currently lists 484 recruiting carboplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carboplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carboplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.